Ulcerative Colitis – Landscape & Forecast – Disease Landscape & Forecast (G7)

We expect the ulcerative colitis (UC) therapy market to grow steadily over the next decade, primarily driven by the increasing use of non-tumor necrosis factor (TNF) biologics (e.g., Takeda’s Entyvio, Johnson & Johnson Innovative Medicine’s Stelara, AbbVie’s Rinvoq) earlier in the treatment algorithm. Additionally, the availability of Pfizer’s Xeljanz / Xeljanz XR, BMS’s Zeposia, Alfasigma’s Jyseleca, Pfizer’s Velsipity, and Eli Lilly’s Omvoh has expanded the treatment armamentarium and intensified market competition. Furthermore, the recent approvals of AbbVie’s Skyrizi and Johnson & Johnson Innovative Medicine’s Tremfya and the expected launch of several therapies with novel mechanisms of action (e.g., ABX464, ivarmacitinib, MK-7240) will drive market growth over the next 10 years. Offsetting this growth will be the continued generic erosion of conventional agents and the entry of less expensive biosimilars.

QUESTIONS ANSWERED

• What are the similarities and differences in how U.S., European, and Japanese gastroenterologists treat UC?
• How do gastroenterologists perceive biosimilar agents, and what has been / will be their impact on the UC market?
• What are experts’ insights into current treatments for TNF-refractory UC (e.g., Pfizer’s Xeljanz / Xeljanz XR, Takeda’s Entyvio, Johnson & Johnson Innovative Medicine’s Stelara, AbbVie’s Rinvoq, BMS’s Zeposia, Alfasigma’s Jyseleca, Pfizer’s Velsipity, Eli Lilly’s Omvoh, AbbVie’s Skyrizi, Johnson & Johnson Innovative Medicine’s Tremfya)? What factors drive their treatment decisions?
• What are experts’ perceptions of key emerging therapies (e.g., Abivax’s ABX464, Merck’s MK-7240), and where do they see these agents fitting into the treatment algorithm?
• How will the market evolve over the next 10 years?

CONTENT HIGHLIGHTS

Geographies: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 27 country-specific interviews with thought-leading gastroenterologists supported by survey data collected for this and other Clarivate research.

Epidemiology: Diagnosed prevalence of UC by country.

Forecast: 10-year, annualized, drug-level sales and patient share of key UC therapies through 2034, segmented by brands / generics / biosimilars, and acute and maintenance settings.

Drug treatments: Coverage of key current and emerging therapies

PRODUCT DESCRIPTION

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.